Wire · opportunities
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
Valion Bio appointed Thomas H. Jensen as Board Chair, leveraging his biotech turnaround experience to advance Entolimod, a clinical-stage biologic with FDA Fast Track and Orphan Drug designations for treating acute radiation syndrome. Jensen's leadership aims to build on Valion's scientific and operational foundation with clear milestones and resource discipline.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your biotech venture faces a pathway to renewed focus and milestone clarity as Valion’s new chair applies proven turnaround skills. Accelerate planning to match operational discipline with drug potential in a field lacking FDA-approved treatments.
◆ Coverage
2 sources · 5 Oct 2026
◆ Related on Wire
◆ Topics